US LNG exports surge but will buyers in China turn up?
Investing.com - Aytu BioScience reported on Tuesday first quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Aytu BioScience announced earnings per share of $-0.490 on revenue of $27.45M. Analysts polled by Investing.com EPS of $-0.370 on revenue of $25.5M.
Aytu BioScience 's are down 53.76% and is trading at $0.190 , still down 93.79% from its 52 week high of $3.06 set on Tuesday, September 28, 2021.
Aytu BioScience follows other major Healthcare sector earnings this month
Aytu BioScience's report follows an earnings beat by Merck ADR on Friday, September 9, 2022, who reported EPS of $0.5392 on revenue of $5.69B, EPS of $0.5165 on revenue of $5.57B.
Veeva Systems A had beat expectations on Wednesday, August 31, 2022 with second quarter EPS of $1.03 on revenue of $534.22M, for EPS of $1.01 on revenue of $530.71M.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar